NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Q: How much funding does NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) provide?

The listing does not state a funding amount. Check the funder's announcement for specifics.

Q: When is the deadline for NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)?

The deadline is January 7, 2027.

Q: Who is eligible for NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)?

Eligible applicants: Private colleges & universities; County governments; City & township governments; School districts; For-profit businesses; Tribal governments; Nonprofits without 501(c)(3) status; State governments.

National Institutes of Health

Federal

Funding Amount

Not stated

Deadline

January 7, 2027

94 days left

Grant Type

Federal

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

Private colleges & universities
County governments
City & township governments
School districts
For-profit businesses
Tribal governments
Nonprofits without 501(c)(3) status
State governments

Geography

Non-domestic (non-U.S.) components of U.S.

Other requirements

Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Not eligible / not funded

Not eligible: Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Overview

This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Details

Agency: National Institutes of Health
Department: Department of Health and Human Services
Opportunity #: PAR-25-032
Instrument: grant

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.